Halocore

Biopharma sponsors can assemble large submissions whose modules, claims, evidence and formatting must remain internally consistent. The supplied research confirms that a regulator deployed new AI-assisted review systems while keeping human reviewers in the loop, and that no public submission-behavior interface exists. It also confirms a final public AI-credibility framework and finds no reviewed SaaS pre-submission reviewer.

Halocore must not describe itself as a replica or simulator of the regulator. It uses only public guidance, sponsor-approved rules and documented consistency checks. A draft package remains inside the sponsor's controlled environment; the system indexes permitted sections, compares claims and evidence, flags missing or contradictory references and produces a remediation matrix with source citations and uncertainty.

Source document, extracted statement, consistency hypothesis, regulatory-expert finding, remediation task, approved correction, validated package version, submission, agency acknowledgment, information request and review outcome remain separate. Two independent model passes can reduce one class of omission, but agreement is not truth and disagreement requires review.

The first release should use a synthetic Module 2-style package and a narrow public-guidance checklist. It must retain immutable event evidence, access controls and versioning, but no audit trail alone establishes electronic-record compliance. The sponsor's quality and regulatory authorities own validation, intended use, signoff and submission.

Regulatory operations, medical-writing or quality lead at a biopharma sponsor preparing a high-stakes submission package